Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
about
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapyTax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF-κB activation.Clinical outcomes and correlates of TP53 mutations and cancer.Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.Predicting survival in chronic lymphocytic leukemia.Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.MicroRNAs as potential clinical biomarkers: emerging approaches for their detection.An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesisPrimary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitroClinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Regulating the genome surveillance system: miRNAs and the p53 super family.NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies.Prognostic factors in chronic lymphocytic leukemia-what do we need to know?p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.The mutant p53 mouse as a pre-clinical model.Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia.Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.Epigenetic inactivation of the miR-34a in hematological malignancies.What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.p53 protein expression in chronic lymphocytic leukemia.A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction
P2860
Q28077136-C4E37023-9BBE-4E7E-A631-655182D411D3Q30353061-04EF9F8D-89D9-44DB-981A-72EFCDAF914AQ33693838-3056D6E6-6C5B-41AD-8E1F-8700C3209C87Q33798525-D09B24DE-D15C-4DDE-B9E8-46856C868491Q34257190-FAA14AE6-B4EC-44A9-ABBE-66D318C173CBQ34461989-23A70399-6504-45E3-9BA0-A595DA9AD7B3Q35049753-66296A16-7643-4BCC-B044-0F27FDF2C0E3Q35053672-EBB93DC0-6B77-474F-8F7B-38E8913921DBQ35978724-458303CB-F9F6-4824-A27D-AA62E725465EQ36494000-376AB246-5A24-4692-B82E-A9DE7E88984AQ37413891-6D3DDC0F-D1E9-49BF-A253-97327A8FE84EQ37618663-30FE4490-5437-453A-97A2-CCF30C4B24A7Q37678986-59903A24-AC31-40FD-9F8D-090E855D1AF3Q37690750-A49197DA-5D98-4793-BF41-807E71A2D2F3Q37724203-E2403848-21A5-47DB-B5B1-F4D5EA617D3EQ37801267-BB4BA197-AF00-491B-81D2-1DC32FFE0474Q37874926-332CC69E-4C79-424A-8A8B-5027CD843226Q37978967-4D908FE7-CAD4-4331-A872-86891A8BFE56Q38074014-7F1FCA22-EEFB-405B-9E00-ED2FA24148DDQ38101683-DDBAC444-895F-4E0E-A8FC-E49476237B3BQ38579008-C579AB25-9720-4DB9-A8C4-7A7EDA027A05Q39018419-6E3595B8-3C3C-4172-88E8-8C26D157CB5DQ39169789-63941D3C-4908-4E65-BEB4-1DF8B5DA81E3Q39310339-42668D73-DCD3-4C75-B40C-C8CB47900FA2Q39592668-8AC90618-4658-448F-9644-B42D1B5648FBQ39745821-1445468A-840E-47ED-BEE4-085954DE0A77Q40735558-4244590A-7FC1-4FFE-B8F0-1061400A4711Q54330797-3C14604B-E096-45E6-8975-D000F5A2148CQ58000938-F7459B67-188E-4D4D-ACA5-D70CCCA27116
P2860
Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chronic lymphocytic leukemia a ...... : the role of the p53 pathway.
@en
Chronic lymphocytic leukemia a ...... : the role of the p53 pathway.
@nl
type
label
Chronic lymphocytic leukemia a ...... : the role of the p53 pathway.
@en
Chronic lymphocytic leukemia a ...... : the role of the p53 pathway.
@nl
prefLabel
Chronic lymphocytic leukemia a ...... : the role of the p53 pathway.
@en
Chronic lymphocytic leukemia a ...... : the role of the p53 pathway.
@nl
P50
P356
P1433
P1476
Chronic lymphocytic leukemia a ...... : the role of the p53 pathway.
@en
P2093
Axel Benner
P304
P356
10.4161/CC.7.24.7245
P577
2008-12-21T00:00:00Z